Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

Overview

About this study

The purpose of this study is to determine the effective dose(s) of RPC4046 in the treatment of Eosinophilic Esophagitis (EoE). This trial consists of two phases: 16 weeks of double-blind treatment and 24 weeks of open-label extension.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Histologic evidence of EoE
  • Clinical symptoms of EoE including dysphagia

Exclusion Criteria:

  • Primary causes of esophageal eosinophilia other than EoE

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Francisco Ramirez, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20131485

Mayo Clinic Footer